4.8 Article

BSA-bioinspired gold nanorods loaded with immunoadjuvant for the treatment of melanoma by combined photothermal therapy and immunotherapy

Journal

NANOSCALE
Volume 10, Issue 46, Pages 21640-21647

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c8nr05323e

Keywords

-

Funding

  1. U.S. National Institutes of Health [RS20132225-106, R21 EB 015509-01, R01CA205348-01]
  2. Oklahoma Center for the Advancement of Science and Technology [HR16-085]
  3. National Natural Science Foundation of China [61805161, 61705143]
  4. China Postdoctoral Science Foundation [2017M622766, 2018T110890, 2018M630979]
  5. Shenzhen Basic Research Project [JCYJ20170818143045740]
  6. NATIONAL CANCER INSTITUTE [R01CA205348] Funding Source: NIH RePORTER
  7. NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB015509] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The development of therapeutic methods that can effectively delay tumor growth, inhibit tumor metastases, and protect the host from tumor recurrence still faces challenges. Nanoparticle-based combination therapy may provide an effective therapeutic strategy. Herein, we show that bovine serum albumin (BSA)-bioinspired gold nanorods (GNRs) were loaded with an immunoadjuvant for combined photothermal therapy (PTT) and immunotherapy for the treatment of melanoma. In this work, cetyltrimethylammonium bromide (CTAB)-coated GNRs were successively decorated with polyethylene glycol (PEG) and BSA, and loaded with an immunoadjuvant imiquimod (R837). The synthesized mPEG-GNRs@BSA/R837 nanocomplexes under near-infrared (NIR) irradiation could effectively kill tumors and trigger strong immune responses in treating metastatic melanoma in mice. Furthermore, the nanocomplex-based PTT prevented lung metastasis and induced a strong long-term antitumor immunity to protect the treated mice from tumor recurrence. The nanocomplex-based PTT in combination with immunotherapy may be potentially employed as an effective strategy for the treatment of melanoma and other metastatic cancers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available